Axil Capital's Past News
Axil Capital Launches its Second Life Science Fund (ALHF II)
Axil Capital Advisors K.K. announces the appointment of Mr. Yasuto Hamanishi, former Deputy President & Executive Officer Mizuho Securities Co Ltd, as its Executive Advisor as of November 1, 2022.
Cranebio added to our portfolio companies.
Angiocrine Bioscience added to our portfolio companies.
Portfolio Companies' Past News
TechsoMed Ltd. announces the opening of a new German Subsidiary, as a strategic collaboration with Research Institute Fraunhofer MEVIS.
Angiocrine Bioscience Announces it has been awarded a $15M Grant from the California Institute for Regenerative Medicine for AB-205 Phase 3 Clinical Trial.
LUCA Science presented its research findings at the Annual Meeting of the American Society of Hematology.
Angiocrine Bioscience Announces Poster Presentation of AB-205 Trial during the 64th Annual Meeting of the American Society of Hematology.
JollyGood has initiated a specific clinical study of digital therapeutic VR for depression with Teijin Pharma.
Cranebio presented its latest research results on ovulation date prediction at an academic conference in collaboration with Unicharm Corporation.
TechsoMed Completes Enrollment in United States Pivotal Trial of BioTraceIO Software for Liver Ablation Outcomes Assessment.
TechsoMed Announces Completion of Full Enrollment in Pivotal U.S trial Evaluating its BioTraceIO Software for Liver Ablation Outcomes Assessment in Liver Cancer Patients.
Jolly Good has launched FACEDUO, a VR support program for schizophrenia, with Otsuka Pharmaceutical.
Allgenesis selected as one of the 3 finalists for the Eyecelerator pitch at the American Academy of Ophthalmology conference on September 29, 2022
The educational effects of the medical education VR developed by Jolly Good and Hiroshima University were published as an article in the American Journal of Infection Control, an American medical journal.
Elixiron Immunotherapeutics Announces Orphan Drug Designation Granted to CSF-1R Inhibitor, EI-1071 for the Treatment of Idiopathic Pulmonary Fibrosis
TOP 11 of TAcc+ International Program 2022.
C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDAC™ Degrader for the Treatment of Synovial Sarcoma and SMARCB1-null Tumors.
AACR: C4's multiple myeloma data prompt dosing switch, giving patients a longer treatment reprieve.
Allgenesis announces first patient dosed in the U.S. for the Phase 1b trial evaluating AG-80308 for the treatment of dry eye disease.
Allgenesis Announces First Patient Enrollment in a FIH Phase 2a Trial of AG-73305 for the Treatment of Diabetic Macular Edema.
LUCA Science was featured in an article in BIOCENTURY.
LUCA Science and Kyowa Kirin announce joint research agreement on mitochondrial disease treatment with novel mitochondria modality.
Research on mice that ‘sweat out’ fat wins STAT Madness for University of Pennsylvania.
Angiocrine Bioscience announces first patient dosed in pivotal phase 3 clinical trial of AB-205 and completion of Series B financing.
LUCA Science raised 3.86 billion yen in Series B.
© Axil Capital All Rights Reserved
